Page last updated: 2024-11-05

tranexamic acid and Autosomal Hemophilia A

tranexamic acid has been researched along with Autosomal Hemophilia A in 78 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Research Excerpts

ExcerptRelevanceReference
"A case is presented in which topical tranexamic acid was used to stop local bleeding from a nipple following piercing in a young man with haemophilia."7.79Case report: use of topical tranexamic acid to stop localised bleeding. ( Chitnis, J; Noble, S, 2013)
"Tranexamic acid (an antifibrinolytic agent) is of proven benefit in the treatment of bleeding in patients with congenital and acquired coagulation disorders."7.71Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. ( Cordingley, FT; Leahy, MF; Taparia, M, 2002)
"We examined whether the clot stability in hemophiliacs could be improved by treatment with tranexamic acid (TXA) in combination with recombinant factor VIII (rFVIII)."6.73Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. ( Christiansen, K; Hvas, AM; Ingerslev, J; Norengaard, L; Sørensen, B; Sørensen, HT, 2007)
" The highest-quality evidence is for the use of tranexamic acid in postpartum hemorrhage, which has been shown to decrease bleeding-related mortality in women without bleeding disorders."4.98Inherited Bleeding Disorders in the Obstetric Patient. ( Bannow, BS; Konkle, BA, 2018)
" A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used."4.77Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985)
"The use of a standardized protocol increased the use of tranexamic acid, with a nonstatistically significant reduction in procedural bleeding rate."4.12Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders. ( Bourassa, M; Champagne, PA; Cloutier, S; Demers, C; Desjardins, MP; Néron, H; Pelland-Marcotte, MC; Singbo, NU, 2022)
" In postpartal period an excellent control of bleeding was obtained by regularly administering FVIII concentrate for several days as well by concomitant use of tranexamic acid and oral contraceptive pills in the next 6 weeks."3.85Pregnancy and delivery in a woman with severe haemophilia A. ( Antic, DA; Bodrozic, JN; Djunic, IS; Lekovic, DR; Miljic, PS; Mitrovic, MM; Petronijevic, MA; Petronijevic-Vrzic, SM, 2017)
"A case is presented in which topical tranexamic acid was used to stop local bleeding from a nipple following piercing in a young man with haemophilia."3.79Case report: use of topical tranexamic acid to stop localised bleeding. ( Chitnis, J; Noble, S, 2013)
"Factor VIII:C, epsilon amino-caproic acid or tranexamic acid are prophylactic agents used in preventing hemorrhage pre-operatively in patients with hemophilia A."3.75Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation. ( Günaldi, M; Helvaci, A; Kiskaç, M; Küçükkaya, RD; Yildirim, ND, 2009)
"Tranexamic acid (an antifibrinolytic agent) is of proven benefit in the treatment of bleeding in patients with congenital and acquired coagulation disorders."3.71Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. ( Cordingley, FT; Leahy, MF; Taparia, M, 2002)
"We examined whether the clot stability in hemophiliacs could be improved by treatment with tranexamic acid (TXA) in combination with recombinant factor VIII (rFVIII)."2.73Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. ( Christiansen, K; Hvas, AM; Ingerslev, J; Norengaard, L; Sørensen, B; Sørensen, HT, 2007)
"Neonatal bleeding was described in 6 affected male neonates, mostly after instrumental delivery or emergency CS, but insufficient information was provided to reliably investigate neonatal outcome in relation to management."2.72Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. ( Bloemenkamp, KWM; Driessens, MHE; Duvekot, JJ; Eikenboom, J; Kruip, MJHA; Lely, AT; Makelburg, ABU; Mauser-Bunschoten, EP; Middeldorp, JM; Nieuwenhuizen, L; Peters, M; Punt, MC; Schutgens, REG; van Galen, KPM; Waning, ML, 2021)
"Sixteen patients with haemophilia who required dental scaling participated in this pilot study."2.71Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. ( Boyle, CA; Fiske, J; Lee, AP; Savidge, GF, 2005)
"Case material included 25 patients with hemophilia (9 children and 16 adults) with high-responding inhibitors and 3 patients with acquired factor VIII inhibitors."2.70Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. ( Baudo, F; Gringeri, A; Morfini, M; Rocino, A; Santagostino, E; Scaraggi, FA, 2001)
"The bleeding was effectively controlled within 1 to 48 h in five of nine bleeding episodes."2.69Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. ( Angchaisuksiri, P; Chuansumrit, A; Hathirat, P; Isarangkura, P; Jorgensen, LN; Sriudomporn, N; Tanpowpong, K, 2000)
"A total of 59 participants with haemophilia undergoing dental extraction were involved."2.55Preventing perioperative bleeding in patients with inherited bleeding disorders. ( Beacher, N; Watterson, C, 2017)
"In people with haemophilia or other congenital bleeding disorders undergoing surgical interventions, haemostatic treatment is needed in order to correct the underlying coagulation abnormalities and minimise the bleeding risk."2.52Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. ( Coppola, A; Di Minno, MN; Tufano, A; Windyga, J; Yeung, C, 2015)
"Ninety-two hemophilia A patients who underwent total knee arthroplasty in our center were included."1.72Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors. ( Lv, SJ; Shen, SN; Tong, PJ; Wu, DX, 2022)
"Patients with severe haemophilia have impaired haemostatic response, delayed clot formation and fibrin clots that are vulnerable to fibrinolysis."1.62Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study. ( Bolbos, R; Bordet, JC; Brevet, M; Dargaud, Y; Enjolras, N; Janbain, M, 2021)
"To examine UK haemophilia centre registration patterns and current practice for UBD patients."1.62Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders. ( Desborough, M; Downes, K; Evans, G; Gidley, G; Lowe, G; MacDonald, S; O'Donnell, JS; Obaji, S; Palmer, B; Pinto, F; Thomas, W, 2021)
"Acquired haemophilia A is a rare but important diagnosis, carrying a mortality rate of 22%."1.56 ( Howden, WB; Kam, J; Leith, N; Singh, S, 2020)
"Approximately 50% of female carriers of hemophilia A have factor VIII (FVIII) levels below 0."1.56Hemophilia A in Females: Considerations for Clinical Management. ( Boukouvala, A; Bryant, P; McDaniel, J; Nance, D, 2020)
"This study sought to identify hemophilia carriers in Côte d'Ivoire in order to collect data on demographics, bleeding phenotype, and laboratory results."1.51Hemophilia carrier's awareness, diagnosis, and management in emerging countries: a cross-sectional study in Côte d'Ivoire (Ivory Coast). ( Adjambri, E; Eeckhoudt, S; Hermans, C; Lambert, C; Lobet, S; Meité, ND; Sanogo, I, 2019)
"Thirty-four patients with haemophilia A undergoing 24 TKA and 18 THA were evaluated in this retrospective study (No."1.51Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia. ( Huang, Q; Huang, ZY; Ma, J; Pei, FX; Shen, B; Zeng, HJ; Zhou, ZK, 2019)
"In mice, induced and congenital hemophilia models were combined with fibrinolytic attenuation achieved either genetically or pharmacologically (tranexamic acid [TXA])."1.48Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents. ( Bojko, B; Flick, MJ; Goryńska, PZ; Goryński, K; Knudsen, T; Ley, CD; Olsen, LH; Stagaard, R, 2018)
"Haemophilia is characterised by defective thrombin generation, reduced clot stability and spontaneous bleeding."1.40An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A. ( Bevan, DH; Foley, JH; Rea, CJ; Sørensen, B, 2014)
"Healthy volunteers (N = 5) and haemophilia inhibitor patients (N = 6) were enrolled in a prospective case crossover design."1.40Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. ( Bjørnsen, S; Holme, PA; Pripp, AH; Rea, CJ; Sørensen, B; Tjønnfjord, GE; Tran, HT; Ueland, T, 2014)
"The management of bleeding in haemophilia patients with inhibitors can be challenging when using monotherapy with either activated prothrombin complex concentrate (APCC) or recombinant activated FVII (rFVIIa) fail."1.38Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience. ( Holme, PA; Holmström, M; Tran, HT, 2012)
"Defective hemostasis in haemophilia patients with FVIII inhibitors results in a dramatic decrease in thrombin generation forming unstable fibrin clots that are susceptible to fibrinolyisis."1.37Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma. ( Bevan, D; Dai, L; Mitchell, M; Rangarajan, S; Sørensen, B, 2011)
"However, thrombosis has occurred in three of 12 such patients."1.35Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. ( Bar-Zakay, B; Horowitz, Z; Korianski, Y; Livnat, T; Mor, Y; Salomon, O; Seligsohn, U; Tamarin, I; Winckler, H, 2009)
"Dental extraction in hemophiliacs is associated with a high risk of bleeding."1.33Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002). ( Berthier, AM; De Mello, G; Frachon, X; Garnier, J; Hourdin-Eude, S; Lejeune, S; Mézière, X; Pommereuil, M; Quéro, J, 2005)
"Acquired haemophilia was diagnosed following detailed investigation of a post-partum haemorrhage unresponsive to standard management."1.31Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage. ( Howland, EJ; Keay, SD; Lumley, M; Palmer, J, 2002)
"Two patients with hemophilia A complicated with high-titer alloantibodies have been treated by repeated infusions of microgram quantities of pure human Factor VIIa."1.27Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. ( Hedner, U; Kisiel, W, 1983)

Research

Studies (78)

TimeframeStudies, this research(%)All Research%
pre-199021 (26.92)18.7374
1990's4 (5.13)18.2507
2000's17 (21.79)29.6817
2010's26 (33.33)24.3611
2020's10 (12.82)2.80

Authors

AuthorsStudies
Janbain, M1
Enjolras, N1
Bolbos, R1
Brevet, M1
Bordet, JC1
Dargaud, Y1
Shen, SN1
Wu, DX1
Lv, SJ1
Tong, PJ1
Champagne, PA1
Bourassa, M1
Desjardins, MP1
Cloutier, S1
Demers, C1
Singbo, NU1
Néron, H1
Pelland-Marcotte, MC1
Waberski, AT1
Busack, C1
d'Acoz, YD1
Matisoff, AJ1
Castle, D1
Desborough, MJR1
Kemp, M1
Lowe, G2
Thomas, W2
Obaji, S2
Huang, ZY1
Huang, Q1
Zeng, HJ1
Ma, J1
Shen, B1
Zhou, ZK1
Pei, FX1
Bryant, P1
Boukouvala, A1
McDaniel, J1
Nance, D1
Marlière, C1
Maindiaux, L1
Lambert, C2
Hermans, C2
Howden, WB1
Kam, J1
Leith, N1
Singh, S1
Punt, MC1
Waning, ML1
Mauser-Bunschoten, EP2
Kruip, MJHA1
Eikenboom, J1
Nieuwenhuizen, L1
Makelburg, ABU1
Driessens, MHE1
Duvekot, JJ1
Peters, M1
Middeldorp, JM1
Bloemenkamp, KWM1
Schutgens, REG1
Lely, AT1
van Galen, KPM1
Downes, K1
Evans, G1
Gidley, G1
MacDonald, S1
O'Donnell, JS1
Palmer, B1
Pinto, F1
Desborough, M1
Watterson, C1
Beacher, N1
Stagaard, R1
Flick, MJ1
Bojko, B1
Goryński, K1
Goryńska, PZ1
Ley, CD1
Olsen, LH1
Knudsen, T1
Lewandowski, B1
Wojnar, J1
Brodowski, R1
Mucha, M1
Czenczek-Lewandowska, E1
Brzęcka, D1
Bannow, BS1
Konkle, BA1
Meité, ND1
Sanogo, I1
Lobet, S1
Adjambri, E1
Eeckhoudt, S1
Fisher, C1
Mo, A1
Warrillow, S1
Smith, C1
Jones, D1
Rea, CJ2
Foley, JH1
Bevan, DH1
Sørensen, B4
Tran, HT2
Bjørnsen, S1
Ueland, T1
Pripp, AH1
Tjønnfjord, GE1
Holme, PA2
Koyama, T1
Clerico, C1
Benatar, M1
Dumontier, C1
Freeman, A1
Coppola, A1
Windyga, J2
Tufano, A1
Yeung, C1
Di Minno, MN1
Rath, A1
Nakamura, L1
van der Werf-Grohmann, N1
Zieger, B1
van Galen, KP1
Engelen, ET1
van Es, RJ1
Schutgens, RE1
Rodriguez-Merchan, EC1
Romero-Garrido, JA1
Gomez-Cardero, P1
Sagheer, S1
Atkins, A1
McRae, S1
Stefanska-Windyga, E1
Odnoczko, E1
Baran, B1
Czubak, G1
Bodrozic, JN1
Miljic, PS1
Lekovic, DR1
Petronijevic, MA1
Antic, DA1
Mitrovic, MM1
Petronijevic-Vrzic, SM1
Djunic, IS1
Fuentes García, D1
Ramírez Muñoz, G1
Livnat, T1
Tamarin, I1
Mor, Y1
Winckler, H1
Horowitz, Z1
Korianski, Y1
Bar-Zakay, B1
Seligsohn, U1
Salomon, O1
Günaldi, M1
Helvaci, A1
Yildirim, ND1
Kiskaç, M1
Küçükkaya, RD1
Yilmaz, D1
Akin, M1
Ay, Y1
Balkan, C1
Celik, A1
Ergün, O1
Kavakli, K1
Dai, L1
Bevan, D1
Rangarajan, S1
Mitchell, M1
Diplaris, KT1
Karfis, EA1
Ampatzidou, F1
Ananiadou, OG1
Vakalopoulou, S1
Madesis, A1
Asteri, T1
Drossos, G1
Holmström, M1
Cakr, O1
Kazancoğlu, HO1
Ak, G1
Zülfikar, B1
Bajkin, BV1
Rajic, NV1
Vujkov, SB1
Noble, S1
Chitnis, J1
Taparia, M1
Cordingley, FT1
Leahy, MF1
Mannucci, PM1
Frachon, X1
Pommereuil, M1
Berthier, AM1
Lejeune, S1
Hourdin-Eude, S1
Quéro, J1
Mézière, X1
De Mello, G1
Garnier, J1
Lee, AP1
Boyle, CA1
Savidge, GF1
Fiske, J1
De Bels, D1
Demeere, JL1
Dugauquier, J1
Louis, P1
Van der Vorst, E1
Coetzee, MJ1
Schulman, S1
Hvas, AM1
Sørensen, HT1
Norengaard, L1
Christiansen, K1
Ingerslev, J6
Shankar, S1
Lee, R1
Hedner, U1
Kisiel, W1
Ikemura, K1
Shirahata, A1
Nakamura, T1
Guillaume, M1
Devos, R1
Rizza, CR1
Prinsley, P1
Wood, M1
Lee, CA1
Waly, NG1
Chuansumrit, A1
Isarangkura, P1
Angchaisuksiri, P1
Sriudomporn, N1
Tanpowpong, K1
Hathirat, P1
Jorgensen, LN1
Tagariello, G1
De Biasi, E1
Gajo, GB1
Risato, R1
Radossi, P1
Davoli, PG1
Traldi, A1
Odabaş, AR1
Cetinkaya, R1
Selçuk, Y1
Kaya, H1
Coşkun , U1
Stubbs, M1
Lloyd, J1
Santagostino, E1
Morfini, M1
Rocino, A1
Baudo, F2
Scaraggi, FA1
Gringeri, A1
Howland, EJ1
Palmer, J1
Lumley, M1
Keay, SD1
Boulton, FE1
Smith, A1
Nilsson, IM1
Mikaelsson, M1
Vilhardt, H1
Walter, H1
Prentice, CR1
Feldstedt, M1
Sindet-Pedersen, S6
Casdorph, DL1
deCataldo, F1
Landonio, G1
Muti, G1
Ramström, G2
Blombäck, M2
Verstraete, M1
Stenbjerg, S3
Prince, S1
Pignanelli, M1
Rota, L1
Pignanelli, C1
Vinckier, F1
Vermylen, J1
Peterson, J1
Evans, BE1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
National Study of Moderate and Severe Von Willebrand Disease in the Netherlands[NCT00510042]1,100 participants (Anticipated)Observational2007-07-31Completed
Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458]265 participants (Actual)Observational2012-11-05Active, not recruiting
Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599]40 participants (Actual)Interventional2011-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Centralized Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)1.63

Centralized Factor VIII (FVIII) Antigen (FVIII:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)3.64

Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)2.43

Centralized Von Willebrand Factor (VWF) Propeptide Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)7.3

Centralized Von Willebrand Factor Antigen (VWF:Ag) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis

Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)

InterventionIU/dL (Mean)
Type 3 Von Willebrand's Disease (VWD3)1.29

Local Laboratory Tests for Type 3 Von Willebrand's Disease (VWD3) Diagnosis (Composite)

"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)

InterventionParticipants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)265

Number of Patients With Available Local Laboratory Test for Anti-Von Willebrand Factor (Anti-VWF) Antibodies

Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)

InterventionParticipants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)4

Patients Experiencing Allergic Reactions During Use of Von Willebrand Factor (VWF)-Containing Concentrates

Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)

InterventionParticipants (Count of Participants)
Type 3 Von Willebrand's Disease (VWD3)41

Number of Participants With Previous Use of Blood Products

Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)

InterventionParticipants (Count of Participants)
Packed red cellsCryoprecipitatesFresh frozen plasmaPlatelet concentrates
Type 3 Von Willebrand's Disease (VWD3)24123101

Reviews

10 reviews available for tranexamic acid and Autosomal Hemophilia A

ArticleYear
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review.
    Blood reviews, 2021, Volume: 49

    Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Delivery, Obstetric; Female; Hemophilia A; Hemor

2021
Preventing perioperative bleeding in patients with inherited bleeding disorders.
    Evidence-based dentistry, 2017, Volume: 18, Issue:1

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Hemophilia A; Humans; Postoperativ

2017
Inherited Bleeding Disorders in the Obstetric Patient.
    Transfusion medicine reviews, 2018, Volume: 32, Issue:4

    Topics: Blood Coagulation; Deamino Arginine Vasopressin; Female; Fibrinolytic Agents; Hematology; Hemophilia

2018
[Treatment of acquired inhibitors of coagulation factors].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Antifibrinolytic Agents; Autoantibodies; Blood Coagulation F

2014
Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery.
    The Cochrane database of systematic reviews, 2015, Feb-09, Issue:2

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor VIIa; Hemophilia A; Hemophi

2015
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    The Cochrane database of systematic reviews, 2015, Dec-24, Issue:12

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Factor IX; Factor VIII; Hemophilia

2015
Treatment of von Willebrand's Disease.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo

2004
Treatment of von Willebrand's Disease.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo

2004
Treatment of von Willebrand's Disease.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo

2004
Treatment of von Willebrand's Disease.
    The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7

    Topics: Aminocaproates; Blood Component Transfusion; Deamino Arginine Vasopressin; Factor VIII; Female; Hemo

2004
Inhibitors of fibrinolysis in the treatment of haemophilia.
    Journal of clinical pathology. Supplement (Royal College of Pathologists), 1980, Volume: 14

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Hematuria; Hemophilia A; Humans; Surgical Procedures, Op

1980
Indications for antifibrinolytic therapy.
    Thrombosis et diathesis haemorrhagica, 1975, Dec-15, Volume: 34, Issue:3

    Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav

1975
Clinical application of inhibitors of fibrinolysis.
    Drugs, 1985, Volume: 29, Issue:3

    Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser

1985

Trials

5 trials available for tranexamic acid and Autosomal Hemophilia A

ArticleYear
Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash.
    British dental journal, 2005, Jan-08, Volume: 198, Issue:1

    Topics: Adolescent; Adult; Aged; Cross-Over Studies; Dental Care for Chronically Ill; Dental Scaling; Double

2005
Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.
    Journal of thrombosis and haemostasis : JTH, 2007, Volume: 5, Issue:12

    Topics: Adult; Antifibrinolytic Agents; Blood Coagulation; Drug Therapy, Combination; Factor VIII; Fibrinoly

2007
Local antifibrinolytic treatment with tranexamic acid in hemophilic children undergoing dental extractions.
    Egyptian dental journal, 1995, Volume: 41, Issue:1

    Topics: Administration, Oral; Administration, Topical; Antifibrinolytic Agents; Child; Child, Preschool; Fac

1995
Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2000, Volume: 6, Issue:2

    Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Child, Preschool; Disease Management; Fact

2000
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:4

    Topics: Adult; Antigens; Blood Loss, Surgical; Child; Child, Preschool; Drug Administration Schedule; Electi

2001

Other Studies

63 other studies available for tranexamic acid and Autosomal Hemophilia A

ArticleYear
Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2021, Volume: 27, Issue:6

    Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Factor VIII; Hemophilia A; Hemos

2021
Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors.
    BMC musculoskeletal disorders, 2022, Jun-17, Volume: 23, Issue:1

    Topics: Aged; Antifibrinolytic Agents; Arthritis; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blo

2022
Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2022, Volume: 28, Issue:5

    Topics: Adult; Dentistry; Female; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Retrospective Studies

2022
Massive Clot Formation Following FEIBA and Tranexamic Acid Administration in Postcardiopulmonary Bypass Hemorrhage.
    Journal of cardiothoracic and vascular anesthesia, 2022, Volume: 36, Issue:10

    Topics: Blood Coagulation Factors; Factor VIII; Hemophilia A; Hemorrhage; Humans; Tranexamic Acid

2022
Outcomes and management of pregnancy in women with bleeding disorder of unknown cause.
    Journal of thrombosis and haemostasis : JTH, 2022, Volume: 20, Issue:11

    Topics: Deamino Arginine Vasopressin; Female; Hemophilia A; Hemostatics; Humans; Postpartum Hemorrhage; Preg

2022
Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia.
    BMC musculoskeletal disorders, 2019, Sep-04, Volume: 20, Issue:1

    Topics: Administration, Intravenous; Adult; Antifibrinolytic Agents; Arthralgia; Arthroplasty, Replacement,

2019
Hemophilia A in Females: Considerations for Clinical Management.
    Acta haematologica, 2020, Volume: 143, Issue:3

    Topics: Adolescent; Aged; Chromosome Inversion; Deamino Arginine Vasopressin; Disease Management; Drug Subst

2020
EHL-FIX in haemophilia B carriers with FIX deficiency.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2020, Volume: 26, Issue:2

    Topics: Adolescent; Adult; Antifibrinolytic Agents; Child; Factor IX; Female; Half-Life; Hemophilia A; Hemop

2020
    BMJ case reports, 2020, May-04, Volume: 13, Issue:5

    Topics: Aged, 80 and over; Airway Obstruction; Antifibrinolytic Agents; Cyclophosphamide; Glucocorticoids; H

2020
Current practice and registration patterns among United Kingdom Haemophilia Centre Doctors' Organisation centers for patients with unclassified bleeding disorders.
    Journal of thrombosis and haemostasis : JTH, 2021, Volume: 19, Issue:11

    Topics: Anticoagulants; Female; Hemophilia A; Humans; Pregnancy; Tranexamic Acid; United Kingdom; Venous Thr

2021
Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
    Journal of thrombosis and haemostasis : JTH, 2018, Volume: 16, Issue:7

    Topics: Animals; Antifibrinolytic Agents; Coagulants; Disease Models, Animal; Factor VIIa; Factor VIII; Fibr

2018
Dental extractions in patients with mild hemophilia A and hemophilia B and von Willebrand disease without clotting factor supplementation.
    Polish archives of internal medicine, 2018, 08-31, Volume: 128, Issue:7-8

    Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Dental Caries; Female; Hemop

2018
Hemophilia carrier's awareness, diagnosis, and management in emerging countries: a cross-sectional study in Côte d'Ivoire (Ivory Coast).
    Orphanet journal of rare diseases, 2019, 02-01, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Awareness; Cote d'Ivoire; Cross-Sectional Studies; Factor VIII; Female; Hemophili

2019
Utility of thromboelastography in managing acquired Factor VIII inhibitor associated massive haemorrhage.
    Anaesthesia and intensive care, 2013, Volume: 41, Issue:6

    Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Transfusion; Endometrial Neoplasms; Factor

2013
An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
    Annals of hematology, 2014, Volume: 93, Issue:4

    Topics: Adolescent; Adult; Antifibrinolytic Agents; Drug Therapy, Combination; Factor VIIa; Factor VIII; Hem

2014
Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2014, Volume: 20, Issue:3

    Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Factor Inhibitors; Blood Coagulation Factors; Cros

2014
Radial artery pseudoaneurysm: a rare complication after arthroscopic treatment of a volar wrist ganglion in a hemophilia patient.
    Chirurgie de la main, 2014, Volume: 33, Issue:5

    Topics: Adult; Aneurysm, False; Antifibrinolytic Agents; Arthroscopy; Ganglion Cysts; Hemophilia A; Humans;

2014
Acquired haemophilia A presenting at a District General Hospital.
    BMJ case reports, 2015, Feb-17, Volume: 2015

    Topics: Adrenal Cortex Hormones; Antifibrinolytic Agents; Blood Coagulation Factors; C-Reactive Protein; Dia

2015
Acute "Tumour-like" Tongue Haematoma: The Challenge to Diagnose Haemophilia A.
    Klinische Padiatrie, 2015, Volume: 227, Issue:6-7

    Topics: Child, Preschool; Diagnosis, Differential; Drug Therapy, Combination; Hemophilia A; Humans; Male; Or

2015
Multimodal blood loss prevention approach including intra-articular tranexamic acid in primary total knee arthroplasty for patients with severe haemophilia A.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:4

    Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Case-Control Studies

2016
Successful use of tranexamic acid in the management of haemophilic pseudotumour.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:4

    Topics: Abdomen; Aged; Animals; Antibodies, Neutralizing; Antifibrinolytic Agents; Coagulants; Cysts; Factor

2016
Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2016, Volume: 22, Issue:5

    Topics: Adult; Antibodies, Neutralizing; Antifibrinolytic Agents; Blood Coagulation Factors; Coagulants; Dos

2016
Pregnancy and delivery in a woman with severe haemophilia A.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2017, Volume: 28, Issue:6

    Topics: Adult; Factor VIII; Female; Hemophilia A; Hemorrhage; Humans; Pregnancy; Pregnancy Complications, He

2017
[Type A hemophilia in a man undergoing liver resection for metastasis: implications for anesthetic management].
    Revista espanola de anestesiologia y reanimacion, 2009, Volume: 56, Issue:3

    Topics: Adenocarcinoma; Aged; Anesthesia, General; Blood Loss, Surgical; Colorectal Neoplasms; Deamino Argin

2009
Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies.
    Thrombosis and haemostasis, 2009, Volume: 102, Issue:3

    Topics: Alleles; Blood Loss, Surgical; Factor VIIa; Factor XI; Factor XI Deficiency; Female; Hemophilia A; H

2009
Acute myocardial infarction in a patient with hemophilia A and factor V Leiden mutation.
    Cardiology journal, 2009, Volume: 16, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Antifibrinolytic Agents; Blood Loss, Surgical; Coagulants; Coronary

2009
A single centre experience in circumcision of haemophilia patients: Izmir protocol.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2010, Volume: 16, Issue:6

    Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Circumcision, Male; Factor I

2010
Stabilization of fibrin clots by activated prothrombin complex concentrate and tranexamic acid in FVIII inhibitor plasma.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2011, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Aged; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Fibr

2011
Acute type-a dissection in a patient with severe hemophilia A.
    Journal of cardiothoracic and vascular anesthesia, 2012, Volume: 26, Issue:4

    Topics: Acute Disease; Aortic Aneurysm; Aortic Dissection; Factor VIII; Hemophilia A; Humans; Male; Middle A

2012
Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2012, Volume: 18, Issue:4

    Topics: Adult; Aged; Blood Coagulation Factor Inhibitors; Blood Coagulation Factors; Coagulants; Hemophilia

2012
Treatment of odontogenic large cysts in haemophiliac patients.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2012, Volume: 23, Issue:3

    Topics: Antifibrinolytic Agents; Disease Management; Drug Administration Schedule; Epinephrine; Factor IX; F

2012
Dental extraction in a hemophilia patient without factor replacement therapy: a case report.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:10

    Topics: Adult; Antifibrinolytic Agents; Bicuspid; Curettage; Dental Care for Chronically Ill; Dental Caries;

2012
Case report: use of topical tranexamic acid to stop localised bleeding.
    Emergency medicine journal : EMJ, 2013, Volume: 30, Issue:6

    Topics: Administration, Topical; Antifibrinolytic Agents; Hemophilia A; Hemorrhage; Humans; Male; Nipples; T

2013
Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia.
    European journal of haematology, 2002, Volume: 68, Issue:5

    Topics: Adult; Antifibrinolytic Agents; Autoantibodies; Factor VIII; Hemophilia A; Hemorrhage; Humans; Male;

2002
Management options for dental extraction in hemophiliacs: a study of 55 extractions (2000-2002).
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2005, Volume: 99, Issue:3

    Topics: Adolescent; Adult; Aged; Child; Clinical Protocols; Deamino Arginine Vasopressin; Dental Care for Ch

2005
Continuous infusion of factor VIIIc during heart surgery in a patient with haemophilia A.
    European journal of anaesthesiology, 2004, Volume: 21, Issue:12

    Topics: Anticoagulants; Antifibrinolytic Agents; Blood Loss, Surgical; Cardiac Surgical Procedures; Coronary

2004
The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2007, Volume: 13, Issue:4

    Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Dental Care for Chronically Ill

2007
The onerous task of comparing treatments in inhibitor patients.
    Thrombosis and haemostasis, 2007, Volume: 98, Issue:4

    Topics: Blood Coagulation; Clinical Trials as Topic; Cohort Studies; Factor VII; Factor VIIa; Fibrinolysis;

2007
DDAVP and tranexamic acid for dental extractions in a mild haemophiliac.
    British dental journal, 1984, Jun-23, Volume: 156, Issue:12

    Topics: Adult; Arginine Vasopressin; Cyclohexanecarboxylic Acids; Deamino Arginine Vasopressin; Dental Care

1984
Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
    The Journal of clinical investigation, 1983, Volume: 71, Issue:6

    Topics: Adolescent; Antigens; Child; Factor VII; Factor VIIa; Factor VIII; Hemophilia A; Humans; Isoantibodi

1983
Repair of a cleft palate in a child with hemophilia A.
    Journal of UOEH, 1983, Jun-01, Volume: 5, Issue:2

    Topics: Child, Preschool; Cleft Palate; Dose-Response Relationship, Drug; Factor VIII; Hemophilia A; Hemosta

1983
[A case of acquired hemophilia].
    Acta clinica Belgica, 1984, Volume: 39, Issue:6

    Topics: Aged; Blood Transfusion; Erythrocyte Transfusion; Factor VIII; Female; Hemophilia A; Humans; Tranexa

1984
Adenotonsillectomy in patients with inherited bleeding disorders.
    Clinical otolaryngology and allied sciences, 1993, Volume: 18, Issue:3

    Topics: Adenoidectomy; Blood Coagulation Disorders; Child; Child, Preschool; Deamino Arginine Vasopressin; F

1993
Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases.
    Haemophilia : the official journal of the World Federation of Hemophilia, 2000, Volume: 6, Issue:5

    Topics: Adult; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Factor VIIa; Factor VIII; Hemophilia A;

2000
Tranexamic-acid-induced acute renal cortical necrosis in a patient with haemophilia A.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:1

    Topics: Acute Disease; Adult; Antifibrinolytic Agents; Hemophilia A; Humans; Kidney Cortex Necrosis; Male; T

2001
A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B.
    Australian dental journal, 2001, Volume: 46, Issue:1

    Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Clinical Protocols; Deamino Arginine Vasopressin;

2001
Acquired factor VIII inhibitors as a cause of primary post-partum haemorrhage.
    European journal of obstetrics, gynecology, and reproductive biology, 2002, Jun-10, Volume: 103, Issue:1

    Topics: Adult; Autoantibodies; Deamino Arginine Vasopressin; Factor VIII; Female; Hemophilia A; Hemostatics;

2002
DDAVP and cryoprecipitate in mild haemophilia.
    Lancet (London, England), 1979, Sep-08, Volume: 2, Issue:8141

    Topics: Arginine Vasopressin; Blood Preservation; Cryoglobulins; Deamino Arginine Vasopressin; Factor VIII;

1979
DDAVP factor VIII concentrate and its properties in vivo and in vitro.
    Thrombosis research, 1979, Volume: 15, Issue:1-2

    Topics: Adolescent; Aged; Arginine Vasopressin; Blood Coagulation; Blood Donors; Child; Deamino Arginine Vas

1979
Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII.
    Lancet (London, England), 1991, Sep-28, Volume: 338, Issue:8770

    Topics: Adult; Dental Care; Factor VIIa; Factor VIII; Hemophilia A; Hemostasis; Humans; Male; Recombinant Pr

1991
Topical aminocaproic acid in hemophiliac patients undergoing dental extraction.
    DICP : the annals of pharmacotherapy, 1990, Volume: 24, Issue:2

    Topics: Administration, Oral; Administration, Topical; Aminocaproates; Hemophilia A; Humans; Injections, Int

1990
Management of oral bleeding in haemophilic patients.
    Lancet (London, England), 1988, Nov-05, Volume: 2, Issue:8619

    Topics: Aprotinin; Cyclohexanecarboxylic Acids; Drug Combinations; Factor XIII; Fibrin Tissue Adhesive; Fibr

1988
Management of oral bleeding in haemophilic patients.
    Lancet (London, England), 1989, Feb-11, Volume: 1, Issue:8633

    Topics: Aprotinin; Drug Combinations; Drug Therapy, Combination; Factor XIII; Fibrin Tissue Adhesive; Fibrin

1989
Management of oral bleeding in haemophilic patients.
    Lancet (London, England), 1988, Sep-03, Volume: 2, Issue:8610

    Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Hemostasis; Humans; Mouthwashes; Oral Hemorrhage; Tranexa

1988
Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1986, Volume: 44, Issue:9

    Topics: Administration, Oral; Administration, Topical; Cyclohexanecarboxylic Acids; Dental Care for Disabled

1986
An alternative to blood product therapy for dental extractions in the mild to moderate haemophiliac patient.
    British dental journal, 1987, Apr-11, Volume: 162, Issue:7

    Topics: Adult; Cyclohexanecarboxylic Acids; Deamino Arginine Vasopressin; Dental Care for Disabled; Hemophil

1987
Control of gingival hemorrhage in hemophilic patients by inhibition of fibrinolysis with tranexamic acid.
    Journal of periodontal research, 1988, Volume: 23, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Fibri

1988
[Extractions in hemophilic patients. Control of hemostasis with DDAVP].
    Dental Cadmos, 1988, Oct-15, Volume: 56, Issue:15

    Topics: Adolescent; Adult; Child; Deamino Arginine Vasopressin; Dental Care for Disabled; Hemophilia A; Hemo

1988
Treatment of bilateral fracture of the mandible in a hemophilic patient with inhibitor to factor VIII.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1987, Volume: 45, Issue:6

    Topics: Adult; Blood Coagulation Factors; Factor VIII; Fracture Fixation; Hemophilia A; Humans; Male; Mandib

1987
Dental extractions in hemophilia: reflections on 10 years' experience.
    Oral surgery, oral medicine, and oral pathology, 1985, Volume: 59, Issue:1

    Topics: Aminocaproic Acid; Bandages; Cellulose, Oxidized; Dental Care for Disabled; Factor IX; Factor VIII;

1985
Tranexamic acid to reduce hemorrhage in hemophiliacs.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1988, Volume: 46, Issue:3

    Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Humans; Oral Hemorrhage; Tranexamic Acid

1988
Oral surgery in hemophiliacs.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 1987, Volume: 45, Issue:3

    Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Humans; Mouth; Oral Hemorrhage; Tranexamic Acid

1987
Tranexamic acid.
    The Medical letter on drugs and therapeutics, 1987, Sep-25, Volume: 29, Issue:749

    Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Hemorrhage; Humans; Premedication; Prospective Studies; T

1987